Reasons why COVID-19 survivors should follow dietary World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) recommendations: from hyper-inflammation to cardiac dysfunctionsVincenzo Quagliariello, Nicola Maurea, Giuseppe Nunnari et al.|PubMed|2021Cited by 10
TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokinesNicola Maurea, Gerardo Botti, Vincenzo Quagliariello et al.|European Heart Journal|2021Cited by 5
Abstract 9384: Evolocumab, a Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitor, Reduces Doxorubicin, Trastuzumab and Nivolumab Induced Cardiotoxicity Through Mtorc1 and Myd88 Related PathwaysNicola Maurea, Vincenzo Quagliariello, Martina Iovine et al.|Circulation|2021Cited by 2
6MO PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathwaysVincenzo Quagliariello, Nicola Maurea, Francesca Cerrone et al.|Annals of Oncology|2021Cited by 1